Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 19;11(9):e007630. doi: 10.1136/jitc-2023-007630

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Kaplan-Meier survival curves depicting distant metastasis free survival (A), time-to-next treatment (B) and overall survival (C) stratified by adjuvant therapy. Result show that median distant-metastasis-free survival (39.0 months, 95% CI 31.0 to NR vs 41.0 months, 95% CI 29.2 to 52.8, p=0.012) and TTNT (33.0, 95% CI 26.6 to 39.4 vs 20.0 months, 95% CI 14.3 to 25.7, p<0.001) were significantly longer for adjuvant TT. By contrast, median overall survival was not reached in both groups. TTNT, time-to-next treatment; TT, targeted therapy.